# Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

> **NCT06569147** · PHASE1,PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 49 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06569147
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569147, "Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06569147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*